{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=55",
    "query": {
      "intervention": "Open Label Extension Study",
      "page": 55
    },
    "page_size": 10
  },
  "pagination": {
    "page": 55,
    "page_size": 10,
    "total_count": 2084,
    "total_pages": 209,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=56&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=54&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-06T06:23:48.767Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00521339",
      "title": "Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis-Type Psoriasis",
        "Plaque-Type Psoriasis"
      ],
      "interventions": [
        {
          "name": "Apremilast",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2007-08-01",
      "completion_date": "2009-05-01",
      "has_results": true,
      "last_update_posted_date": "2020-05-07",
      "last_synced_at": "2026-11-06T06:23:48.767Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • St Louis, Missouri • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00521339"
    },
    {
      "nct_id": "NCT05995353",
      "title": "A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Risankizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 110,
      "start_date": "2023-12-11",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-11-06T06:23:48.767Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Oakland, California + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05995353"
    },
    {
      "nct_id": "NCT04138277",
      "title": "A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pompe Disease (Late-onset)"
      ],
      "interventions": [
        {
          "name": "AT2221",
          "type": "DRUG"
        },
        {
          "name": "ATB200",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Amicus Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2019-12-18",
      "completion_date": "2024-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-11-06T06:23:48.767Z",
      "location_count": 18,
      "location_summary": "Little Rock, Arkansas • Irvine, California • Gainesville, Florida + 14 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04138277"
    },
    {
      "nct_id": "NCT05243719",
      "title": "Open-label Extension Study of ADP101",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Food Allergy"
      ],
      "interventions": [
        {
          "name": "ADP101",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alladapt Immunotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "57 Years",
        "sex": "ALL",
        "summary": "4 Years to 57 Years"
      },
      "enrollment_count": 45,
      "start_date": "2022-03-14",
      "completion_date": "2024-02-27",
      "has_results": false,
      "last_update_posted_date": "2024-03-26",
      "last_synced_at": "2026-11-06T06:23:48.767Z",
      "location_count": 14,
      "location_summary": "Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 11 more",
      "locations": [
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05243719"
    },
    {
      "nct_id": "NCT02003144",
      "title": "An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica",
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "eculizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2015-01-12",
      "completion_date": "2021-07-12",
      "has_results": true,
      "last_update_posted_date": "2022-08-23",
      "last_synced_at": "2026-11-06T06:23:48.767Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • Oceanside, California • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02003144"
    },
    {
      "nct_id": "NCT01462565",
      "title": "Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension, Pulmonary"
      ],
      "interventions": [
        {
          "name": "current marketed FLOLAN (epoprostenol sodium)",
          "type": "DRUG"
        },
        {
          "name": "new thermo stable formulation of epoprostenol sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 16,
      "start_date": "2011-11-01",
      "completion_date": "2012-11-08",
      "has_results": true,
      "last_update_posted_date": "2017-10-16",
      "last_synced_at": "2026-11-06T06:23:48.767Z",
      "location_count": 6,
      "location_summary": "Miami Beach, Florida • Chicago, Illinois • Baltimore, Maryland + 3 more",
      "locations": [
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01462565"
    },
    {
      "nct_id": "NCT02600819",
      "title": "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "E/C/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "B/F/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2015-12-14",
      "completion_date": "2019-10-15",
      "has_results": true,
      "last_update_posted_date": "2020-11-05",
      "last_synced_at": "2026-11-06T06:23:48.767Z",
      "location_count": 19,
      "location_summary": "Los Angeles, California • Sacramento, California • Ft. Pierce, Florida + 16 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02600819"
    },
    {
      "nct_id": "NCT05897424",
      "title": "Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency",
        "Emphysema"
      ],
      "interventions": [
        {
          "name": "SAR447537",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 185,
      "start_date": "2024-06-20",
      "completion_date": "2028-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-11-06T06:23:48.767Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05897424"
    },
    {
      "nct_id": "NCT05199688",
      "title": "A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica Spectrum Disorder",
        "NMOSD"
      ],
      "interventions": [
        {
          "name": "Satralizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "2 Years to 11 Years"
      },
      "enrollment_count": 8,
      "start_date": "2026-05-06",
      "completion_date": "2029-09-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-11-06T06:23:48.767Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05199688"
    },
    {
      "nct_id": "NCT01264679",
      "title": "A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Iron Deficiency Anemia"
      ],
      "interventions": [
        {
          "name": "Ferumoxytol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AMAG Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 8,
      "start_date": "2011-12-27",
      "completion_date": "2015-04-24",
      "has_results": true,
      "last_update_posted_date": "2022-04-28",
      "last_synced_at": "2026-11-06T06:23:48.767Z",
      "location_count": 1,
      "location_summary": "Waltham, Massachusetts",
      "locations": [
        {
          "city": "Waltham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01264679"
    }
  ]
}